

b4

c) introducing said treated PBMC to said patient.

3. (Amended) A method according to claim 2 wherein said suppressive-inducing composition comprises TGF- $\beta$  and IL-2.

a1  
cancel

4. (Amended) A method according to claim 2 further comprising treating said donor cells with a T cell activator.

7. (Amended) A method according to claim 2 wherein said PBMC are enriched for CD8+ cells.

a2

8. (Amended) A method according to claim 2 wherein said PBMC are enriched for CD4+ cells.

B4

10. (Amended) A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

a3

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
- b) treating said PBMC with a suppressive-inducing composition for a time sufficient to generate suppressor cells; and
- c) introducing said suppressor cells to said patient.

11. (Amended) A method according to claim 10 wherein said suppressive-inducing composition comprises TGF- $\beta$ .

12. (Amended) A method according to claim 10 wherein said suppressive-inducing composition comprises a mixture of IL-2 and TGF- $\beta$ .

13. (Amended) A method according to claim 10 further comprising treating said donor cells with a T cell activator.

a4

16. (Amended) A method according to claim 10 wherein said PBMC are enriched for CD8+

cells.

17. (Amended) A method according to claim 10 wherein said PBMC are enriched for CD4+ cells.

Please add the following new claims:

--29. A method according to claim 2 wherein said PBMC are enriched for CD3+CD4-CD8- cells.

30. A method according to claim 10 wherein said PBMC are enriched for CD3+CD4-CD8- cells.

31. A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
- b) selectively enriching said PBMC for CD3+CD4-CD8- cells;
- c) treating said CD3+CD4-CD8- cells with a suppressive-inducing composition comprising TGF- $\beta$  and IL-2 for a time sufficient to induce T cell tolerance in said patient; and
- c) introducing said treated CD3+CD4-CD8- cells to said patient.

32. A method for treating donor cells to ameliorate graft versus host disease in a recipient patient comprising:

- a) removing peripheral blood mononuclear cells (PBMC) from a donor;
- b) selectively enriching said PBMC for CD3+CD4-CD8- cells;
- c) treating said CD3+CD4-CD8- cells with a suppressive-inducing composition for a time sufficient to generate suppressor cells; and
- c) introducing said suppressor cells to said patient.

33. A method according to claim 4 wherein said T cell activator is anti-CD3.